Arix Bioscience Past Earnings Performance
Past criteria checks 2/6
Arix Bioscience's earnings have been declining at an average annual rate of -16.4%, while the Capital Markets industry saw earnings growing at 16.3% annually. Revenues have been declining at an average rate of 21.3% per year. Arix Bioscience's return on equity is 6.3%, and it has net margins of 105.6%.
Key information
-16.4%
Earnings growth rate
-18.5%
EPS growth rate
| Capital Markets Industry Growth | 16.3% |
| Revenue growth rate | -21.3% |
| Return on equity | 6.3% |
| Net Margin | 105.6% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Arix Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 14 | 15 | 6 | 0 |
| 31 Mar 23 | -8 | -6 | 6 | 0 |
| 31 Dec 22 | -31 | -28 | 5 | 0 |
| 30 Sep 22 | -40 | -40 | 5 | 0 |
| 30 Jun 22 | -50 | -53 | 5 | 0 |
| 31 Mar 22 | -52 | -57 | 5 | 0 |
| 31 Dec 21 | -54 | -61 | 5 | 0 |
| 30 Sep 21 | 4 | -11 | 6 | 0 |
| 30 Jun 21 | 61 | 39 | 7 | 0 |
| 31 Mar 21 | 98 | 83 | 7 | 0 |
| 31 Dec 20 | 136 | 126 | 8 | 0 |
| 30 Sep 20 | 78 | 72 | 8 | 0 |
| 30 Jun 20 | 20 | 18 | 9 | 0 |
| 31 Mar 20 | -21 | -26 | 11 | 0 |
| 31 Dec 19 | -62 | -70 | 12 | 0 |
| 30 Sep 19 | -42 | -49 | 14 | 0 |
| 30 Jun 19 | -22 | -28 | 15 | 0 |
| 31 Mar 19 | 15 | 5 | 15 | 0 |
| 31 Dec 18 | 53 | 37 | 15 | 0 |
| 30 Sep 18 | 47 | 31 | 15 | 0 |
| 30 Jun 18 | 42 | 25 | 14 | 0 |
| 31 Mar 18 | 25 | 9 | 14 | 0 |
| 31 Dec 17 | 7 | -7 | 14 | 0 |
| 31 Dec 16 | 1 | -7 | 11 | 0 |
| 31 Mar 16 | 0 | -7 | 6 | 0 |
Quality Earnings: ARIXL has high quality earnings.
Growing Profit Margin: ARIXL became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ARIXL's earnings have declined by 16.4% per year over the past 5 years.
Accelerating Growth: ARIXL has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ARIXL has become profitable in the last year, making it difficult to compare its past year earnings growth to the Capital Markets industry (-5.9%).
Return on Equity
High ROE: ARIXL's Return on Equity (6.3%) is considered low.